CHMP recommendations include HBV drug Vemlidy

EMA's CHMP backed approval of a host of candidates on Friday, including Vemlidy tenofovir alafenamide fumarate (TAF; GS-7340) from Gilead Sciences Inc. (NASDAQ:GILD) to treat HBV.

CHMP recommended Vemlidy's approval

Read the full 296 word article

User Sign In